Week in Review: Mevion Medical of Boston Closes $150 Million Financing from China Investors

Deals and Financings   Mevion Medical, a Boston maker of proton therapy machines, closed a $150 million financing from China private equity investors; Shanghai Kinetic Medical will pay $77 million to acquire Elliquence LLC, a US medical device maker specializing in radiofrequency products; Shunwei Capital and DCM Ventures led a $65.7 million C round in Yaoshibang, a Guangzhou online pharmacy trading and education platform; WuXi Biologics will invest $60 million to build a biologics CDMO operation near Boston , the fourth new plant for WuXi in two months; Aptose Biosciences of San Diego in-licensed greater China rights to a leukemia candidate from Korea 's CrystalGenomics; WuXi AppTec's Corporate Venture Fund led a financing in Insilico Medicine, a Baltimore AI company specializing in drug discovery;   Trials and Approvals   Ascletis Pharma of Hangzhou reported approval for its lead drug, Ganovo® (danoprevir), an innovative treatment for hepatitis C; China approved its first PD-1 immunotherapy: Opdivo, a Bristol-Myers Squibb drug, is indicated as a second-line treatment for NSCLC; CStone Pharma of Suzhou has begun pivotal Phase II studies of its lead drug, a PD-L1 antibody, in two forms of lymphoma; Everest Medicines, a US-China startup that in-licenses drugs for China 's market, filed an IND to start a Phase III clinical trial of its novel antibiotic, eravacycline. Stock Symbols: (SHZ: 300326) (HK: 0656) (HK: 2269) (NSDQ: APTO; TSX: APS) (KOSDAQ: 083790) (SHA: 603259) (NYSE: BMY) Share this with colleagues: // //